Xiang, Y.; Zhang, M.; Wang, Q.; Liu, J.; Zeng, L.; Sun, A.; Lu, K.
First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis. Curr. Oncol. 2025, 32, 148.
https://doi.org/10.3390/curroncol32030148
AMA Style
Xiang Y, Zhang M, Wang Q, Liu J, Zeng L, Sun A, Lu K.
First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis. Current Oncology. 2025; 32(3):148.
https://doi.org/10.3390/curroncol32030148
Chicago/Turabian Style
Xiang, Yan, Meiling Zhang, Qian Wang, Jingwen Liu, Lulin Zeng, Ao Sun, and Kaihua Lu.
2025. "First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis" Current Oncology 32, no. 3: 148.
https://doi.org/10.3390/curroncol32030148
APA Style
Xiang, Y., Zhang, M., Wang, Q., Liu, J., Zeng, L., Sun, A., & Lu, K.
(2025). First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis. Current Oncology, 32(3), 148.
https://doi.org/10.3390/curroncol32030148